FDA Requires GLP-1 Labeling on Possible NAION Risk

Multiple reports describe an FDA-required Warnings and Precautions label change for GLP-1 receptor agonists, including Ozempic, Wegovy, Mounjaro, and Zepbound, concerning possible NAION. Reported absolute event rates are low and evidence does not establish causation; sudden painless vision loss warrants urgent medical attention, but patients should not independently stop treatment. Verify the FDA communication and exact label implementation.